185 related articles for article (PubMed ID: 37305261)
1. Cyanopyridinone- and Cyanopyridine-Based Cancer Cell Pim-1 Inhibitors: Design, Synthesis, Radiolabeling, Biodistribution, and Molecular Modeling Simulation.
Mansour B; Salem YA; Attallah KM; El-Kawy OA; Ibrahim IT; Abdel-Aziz NI
ACS Omega; 2023 Jun; 8(22):19351-19366. PubMed ID: 37305261
[TBL] [Abstract][Full Text] [Related]
2. Utilization of cyanopyridine in design and synthesis of first-in-class anticancer dual acting PIM-1 kinase/HDAC inhibitors.
Bass AKA; Nageeb EM; El-Zoghbi MS; Mohamed MFA; Badr M; Abuo-Rahma GEA
Bioorg Chem; 2022 Feb; 119():105564. PubMed ID: 34959179
[TBL] [Abstract][Full Text] [Related]
3. New cyanopyridine-based scaffold as PIM-1 inhibitors and apoptotic inducers: Synthesis and SARs study.
Farrag AM; Ibrahim MH; Mehany ABM; Ismail MMF
Bioorg Chem; 2020 Dec; 105():104378. PubMed ID: 33099167
[TBL] [Abstract][Full Text] [Related]
4. Development of novel cyanopyridines as PIM-1 kinase inhibitors with potent anti-prostate cancer activity: Synthesis, biological evaluation, nanoparticles formulation and molecular dynamics simulation.
Ibrahim MH; Harras MF; Mostafa SK; Mohyeldin SM; Al Kamaly O; Altwaijry N; Sabour R
Bioorg Chem; 2022 Dec; 129():106122. PubMed ID: 36084418
[TBL] [Abstract][Full Text] [Related]
5. Eco-friendly synthesis of novel cyanopyridine derivatives and their anticancer and PIM-1 kinase inhibitory activities.
Abouzid KAM; Al-Ansary GH; El-Naggar AM
Eur J Med Chem; 2017 Jul; 134():357-365. PubMed ID: 28431341
[TBL] [Abstract][Full Text] [Related]
6. Discovery of PIM-1 kinase inhibitors based on the 2,5-disubstituted 1,3,4-oxadiazole scaffold against prostate cancer: Design, synthesis, in vitro and in vivo cytotoxicity investigation.
Castanet AS; Nafie MS; Said SA; Arafa RK
Eur J Med Chem; 2023 Mar; 250():115220. PubMed ID: 36848846
[TBL] [Abstract][Full Text] [Related]
7. One-Pot Synthesis of Novel Thiazoles as Potential Anti-Cancer Agents.
Sayed AR; Gomha SM; Taher EA; Muhammad ZA; El-Seedi HR; Gaber HM; Ahmed MM
Drug Des Devel Ther; 2020; 14():1363-1375. PubMed ID: 32308369
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel pyrazolo[3,4-b]pyridine scaffold-based derivatives as potential PIM-1 kinase inhibitors in breast cancer MCF-7 cells.
Nafie MS; Amer AM; Mohamed AK; Tantawy ES
Bioorg Med Chem; 2020 Dec; 28(24):115828. PubMed ID: 33166925
[TBL] [Abstract][Full Text] [Related]
9. Characterization of novel heterocyclic compounds based on 4-aryl-4H-chromene scaffold as anticancer agents: Design, synthesis, antiprofilerative activity against resistant cancer cells, dual β-tubulin/c-Src inhibition, cell cycle arrest and apoptosis induction.
Abdelall EKA; A H Elshemy H; Labib MB; E A Mohamed F
Bioorg Chem; 2022 Mar; 120():105591. PubMed ID: 34998122
[TBL] [Abstract][Full Text] [Related]
10. Chalcones bearing nitrogen-containing heterocyclics as multi-targeted inhibitors: Design, synthesis, biological evaluation and molecular docking studies.
Sıcak Y; Kekeçmuhammed H; Karaküçük-İyidoğan A; Taşkın-Tok T; Oruç-Emre EE; Öztürk M
J Mol Recognit; 2023 Jul; 36(7):e3020. PubMed ID: 37092742
[TBL] [Abstract][Full Text] [Related]
11. Imparting aromaticity to 2-pyridone derivatives by
Abdelaziz ME; El-Miligy MMM; Fahmy SM; Abu-Serie MM; Hazzaa AA; Mahran MA
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2304044. PubMed ID: 38230430
[TBL] [Abstract][Full Text] [Related]
12. Saccharomonosporine A inspiration; synthesis of potent analogues as potential PIM kinase inhibitors.
AboulMagd AM; Hassan HM; Sayed AM; Abdelmohsen UR; Abdel-Rahman HM
RSC Adv; 2020 Feb; 10(12):6752-6762. PubMed ID: 35493904
[TBL] [Abstract][Full Text] [Related]
13. Apoptosis: A target for anticancer therapy with novel cyanopyridines.
Ismail MMF; Farrag AM; Harras MF; Ibrahim MH; Mehany ABM
Bioorg Chem; 2020 Jan; 94():103481. PubMed ID: 31837830
[TBL] [Abstract][Full Text] [Related]
14. Discovery of small molecule acting as multitarget inhibitor of colorectal cancer by simultaneous blocking of the key COX-2, 5-LOX and PIM-1 kinase enzymes.
El-Miligy MMM; Al-Kubeisi AK; El-Zemity SR; Nassra RA; Abu-Serie MM; Hazzaa AA
Bioorg Chem; 2021 Oct; 115():105171. PubMed ID: 34303896
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of novel bioactive pyrido[2,3-
Tantawy ES; Nafie MS; Morsy HA; El-Sayed HA; Moustafa AH; Mohammed SM
RSC Adv; 2024 Apr; 14(16):11098-11111. PubMed ID: 38586446
[TBL] [Abstract][Full Text] [Related]
16. Nicotinonitrile-derived apoptotic inducers: Design, synthesis, X-ray crystal structure and Pim kinase inhibition.
Aboukhatwa SM; Ibrahim AO; Aoyama H; Al-Behery AS; Shaldam MA; El-Ashmawy G; Tawfik HO
Bioorg Chem; 2022 Dec; 129():106126. PubMed ID: 36108589
[TBL] [Abstract][Full Text] [Related]
17. Anticancer Effects with Molecular Docking Confirmation of Newly Synthesized Isatin Sulfonamide Molecular Hybrid Derivatives against Hepatic Cancer Cell Lines.
Eldeeb M; Sanad EF; Ragab A; Ammar YA; Mahmoud K; Ali MM; Hamdy NM
Biomedicines; 2022 Mar; 10(3):. PubMed ID: 35327524
[TBL] [Abstract][Full Text] [Related]
18. Annulated pyrazole derivatives as a novel class of urokinase (uPA) inhibitors: Green synthesis, anticancer activity, DNA-damage evaluation, and molecular modelling study.
Farag PS; AboulMagd AM; Hemdan MM; Hassaballah AI
Bioorg Chem; 2023 Jan; 130():106231. PubMed ID: 36335649
[TBL] [Abstract][Full Text] [Related]
19. Benzoxazole/benzothiazole-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations.
El-Helby AA; Sakr H; Eissa IH; Al-Karmalawy AA; El-Adl K
Arch Pharm (Weinheim); 2019 Dec; 352(12):e1900178. PubMed ID: 31596514
[TBL] [Abstract][Full Text] [Related]
20.
Abnous K; Manavi H; Mehri S; Alibolandi M; Kamali H; Ghandadi M; Hadizadeh F
Res Pharm Sci; 2017 Jun; 12(3):196-203. PubMed ID: 28626477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
